Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

Article • Reshaping laboratory efficiency

From bottleneck to breakthrough: a step-by-step path to lab automation

The growing demand for diagnostic testing is pushing laboratories to rethink how they operate – and automation is emerging as the answer. At the Laboratory Equipment and Technology Trade Fair –…

News • Beyond antibiotics

3D micro-bladder model to test phage therapy on recurrent UTIs

A new study shows that phage therapy could help reduce recurrent infections, which happen when the bacteria responsible for UTIs ‘hide’ in the tissue of the bladder.

News • Microbiome map reveals complex interactions

Frenemies in the gut: how bacteria help and hinder each other

A new study sheds light on the complex competition and cooperation between bacteria in the gut microbiome. These insights could be leveraged for targeted manipulation of the microbiome.

Related articles